<DOC>
	<DOCNO>NCT00848042</DOCNO>
	<brief_summary>This open-label , multicenter , single-dose pilot study AuroLase ( TM ) Therapy treatment patient refractory and/or recurrent tumor head neck . Three ( 3 ) treatment group five ( 5 ) patient enrol observed six ( 6 ) month follow treatment . Each group receive single dose AuroShell ( TM ) particles follow one interstitial illumination 808nm laser . Particle dose laser power may increase dose group .</brief_summary>
	<brief_title>Pilot Study AuroLase ( tm ) Therapy Refractory and/or Recurrent Tumors Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Patients must document histological cytological evidence tumor ( ) head neck Patients must one refractory and/or recurrent tumor head neck least one dimension long diameter 15 mm use conventional technique 10 mm spiral CT scan . Target lesion accessible examination ( examination fiber optic nasopharyngoscopy laryngoscopy permit ) biopsy . Each index lesion large enough provide least 6 mg tumor tissue biopsy ( 18 gauge TruCut needle biopsy 1cm length similar technique ) assessment neutron activation analysis . Tumors must measurable accord RECIST criterion Patients must ≥ 18 year age Patients must ECOG Performance Score 0 , 1 2 ( see Appendix 3 ) Patients legal representative must able read , understand sign inform consent Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL Adequate hepatic function evidence : Serum total bilirubin ≤ 2.0 mg/dL , Alkaline phosphatase ≤ 2X ULN reference lab , SGOT/SGPT ≤ 2X ULN reference lab Women childbearing potential must agree use effective form contraception study 90 day follow treatment ( effective form contraception oral contraceptive double barrier method ) . Women NOT childbearing potential undergone bilateral oophorectomy undergone menopause , define absence menstrual cycle 12 consecutive month . Negative pregnancy test woman childbearing potential . Patients know hypersensitivity component PEGylated AuroShell suspension ( polyethylene glycol , gold ) Patients receive concurrent investigational therapy receive investigational therapy within period 5 halflives investigational therapy question prior day dose PEGylated AuroShell particle ( investigational therapy define treatment currently regulatory authority approve indication ) Patients pregnant and/or lactate Patients evidence active bacterial infection fever ≥ 38.5 ºC ( 101.3 ºF ) within 3 day first schedule day dose Patients undergone splenectomy Patient course radiotherapy treatment area within past 30 day . Patient course chemotherapy antineoplastic therapy past 30 day . Patient surgery within 2 cm treatment area within past two week . Life expectancy le 3 month . Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>head neck</keyword>
	<keyword>laser</keyword>
	<keyword>ablation</keyword>
</DOC>